TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06831370: A Multicenter, Single-arm, Open-label, Phase 4 Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin Plus Doxorubicin, Vinblastine and Dacarbazine in Indian Patients With Untreated Stage 3/4 Classical Hodgkin

Sponsor: Takeda · Phase: PHASE4 · Area: ONCOLOGY · Target Enrollment: 124 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$9,240,000

Rescue Site Savings

+$6,098,400

Unlock Full NCT06831370 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06831370 Rescue Dossier →